GlassScriptPhysician profile
Steven Adkins
NPI 1427052786
$311.65
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2020: $93.35 · 2021: $82.41.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $67.93 | 2019-2020 | |
| Astellas Pharma US INC | $52.19 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $46.07 | 2019 | |
| Xeris Pharmaceuticals, INC. | $35.95 | 2021 | |
| Amarin Pharma, INC. | $35.20 | 2020-2021 | |
| Allergan, INC. | $13.88 | 2020 | |
| Merck Sharp & Dohme LLC | $13.27 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.76 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.82 | 2020 | |
| Abbvie INC. | $11.53 | 2021 | |
| Amgen INC. | $11.05 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Adkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.